Net prices of new antiobesity medications.
Inmaculada HernandezSean D SullivanPublished in: Obesity (Silver Spring, Md.) (2024)
The magnitude of manufacturer discounts underscores the need to consider net price information in studies that inform private and public payers' decision-making around coverage of GLP1s for obesity.
Keyphrases
- decision making
- healthcare
- insulin resistance
- metabolic syndrome
- weight loss
- health insurance
- type diabetes
- affordable care act
- weight gain
- high fat diet induced
- mental health
- health information
- case control
- body mass index
- emergency department
- skeletal muscle
- physical activity
- adipose tissue
- social media
- adverse drug